NASDAQ:IMMX Immix Biopharma (IMMX) Stock Price, News & Analysis $2.24 +0.09 (+4.19%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.15▼$2.3050-Day Range$1.81▼$2.5252-Week Range$1.55▼$7.75Volume125,042 shsAverage Volume205,265 shsMarket Capitalization$59.16 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immix Biopharma alerts: Email Address Immix Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside368.8% Upside$10.50 Price TargetShort InterestBearish4.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 5 Articles This WeekInsider TradingAcquiring Shares$36,521 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.88) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.69 out of 5 starsMedical Sector477th out of 936 stocksPharmaceutical Preparations Industry218th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingImmix Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmix Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Immix Biopharma's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.07% of the float of Immix Biopharma has been sold short.Short Interest Ratio / Days to CoverImmix Biopharma has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Immix Biopharma has recently increased by 12.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmix Biopharma does not currently pay a dividend.Dividend GrowthImmix Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMMX. Previous Next 2.6 News and Social Media Coverage News SentimentImmix Biopharma has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Immix Biopharma this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for IMMX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immix Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $36,521.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders55.90% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.26% of the stock of Immix Biopharma is held by institutions.Read more about Immix Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immix Biopharma are expected to grow in the coming year, from ($0.88) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immix Biopharma is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immix Biopharma is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmix Biopharma has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immix Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupDave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Immix Biopharma Stock (NASDAQ:IMMX)Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Read More IMMX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMMX Stock News HeadlinesJuly 25 at 9:36 PM | globenewswire.comCalifornia Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)July 25 at 9:31 PM | globenewswire.comCalifornia Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)July 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.July 17, 2024 | americanbankingnews.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 17.8% in JuneJuly 8, 2024 | globenewswire.comImmix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201June 17, 2024 | globenewswire.comImmix Biopharma to Present at the Stifel 2024 Cell Therapy ForumMay 23, 2024 | finance.yahoo.comImmix Biopharma Insiders Placed Bullish Bets Worth US$625.7kMay 13, 2024 | investorplace.comIMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024July 26, 2024 | Traders Agency (Ad)5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.May 10, 2024 | globenewswire.comImmix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral PresentationApril 29, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple MyelomaApril 29, 2024 | globenewswire.comImmix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple MyelomaApril 18, 2024 | finance.yahoo.comImmix Biopharma, Inc. (IMMX)April 18, 2024 | finanznachrichten.deImmix Biopharma, Inc.: Immix Biopharma on Track to Dose NXC-201 Patients in United StatesApril 18, 2024 | globenewswire.comImmix Biopharma on Track to Dose NXC-201 Patients in United StatesApril 15, 2024 | globenewswire.comImmix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)April 2, 2024 | investorplace.comIMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023March 20, 2024 | globenewswire.comImmix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical TrialSee More Headlines Receive IMMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMMX CUSIPN/A CIK1873835 Webwww.immixbio.com Phone310-651-8041FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$14.00 Low Stock Price Target$7.00 Potential Upside/Downside+381.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-95.00% Return on Assets-78.89% Debt Debt-to-Equity RatioN/A Current Ratio5.82 Quick Ratio5.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book2.69Miscellaneous Outstanding Shares26,410,000Free Float11,649,000Market Cap$57.57 million OptionableOptionable Beta0.17 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Ilya Rachman M.B.A. (Age 51)M.D., MBA, Ph.D., Co-Founder, CEO & Chairman Comp: $637.5kMr. Gabriel Morris B.A. (Age 37)CFO & Director Comp: $637.5kMr. Sean Senn J.D.M.B.A., M.Sc., MBA, MSc, Co-FounderDr. Vladimir P. Torchilin D.Sc. (Age 77)MSE, Ph.D., Scientific Co-Founder Mr. Ben H. Lyon J.D.Executive VP & General CounselDr. Graham Ross FFPM (Age 64)M.D., Chief Medical Officer & Head of Clinical Development Mr. Nandan Oza B.S. (Age 62)Head of Chemistry, Manufacturing & Control Dr. David MarksChief Medical Officer of Cell TherapyMr. Gerhard BauerHead of Cell Thearpy ManufacturingMore ExecutivesKey CompetitorsLandos BiopharmaNASDAQ:LABPBioAtlaNASDAQ:BCABRAPT TherapeuticsNASDAQ:RAPTChromaDexNASDAQ:CDXCGeneration BioNASDAQ:GBIOView All CompetitorsInsiders & InstitutionsIlya M RachmanBought 2,600 shares on 6/7/2024Total: $5,538.00 ($2.13/share)Gabriel S MorrisBought 2,500 shares on 6/7/2024Total: $5,300.00 ($2.12/share)Gabriel S MorrisBought 3,300 shares on 6/4/2024Total: $5,973.00 ($1.81/share)Ilya M RachmanBought 4,300 shares on 5/14/2024Total: $9,675.00 ($2.25/share)Gabriel S MorrisBought 4,500 shares on 5/14/2024Total: $10,035.00 ($2.23/share)View All Insider TransactionsView All Institutional Transactions IMMX Stock Analysis - Frequently Asked Questions How have IMMX shares performed this year? Immix Biopharma's stock was trading at $6.92 on January 1st, 2024. Since then, IMMX shares have decreased by 67.6% and is now trading at $2.24. View the best growth stocks for 2024 here. How were Immix Biopharma's earnings last quarter? Immix Biopharma, Inc. (NASDAQ:IMMX) issued its quarterly earnings data on Thursday, May, 9th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. When did Immix Biopharma IPO? Immix Biopharma (IMMX) raised $23 million in an initial public offering on Thursday, December 16th 2021. The company issued 4,200,000 shares at $5.00-$6.00 per share. How do I buy shares of Immix Biopharma? Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMMX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.